Biomarkers of Epithelial Injury in Chronic Ear Disease

Abstract

Chronic ear diseases, including chronic otitis media and cholesteatoma, are significant causes of morbidity worldwide due to persistent epithelial injury and its sequelae. Recent advances in molecular biology have elucidated a spectrum of biomarkers that reflect epithelial damage, inflammation, and remodeling in the middle ear, offering novel insights into disease mechanisms, diagnosis, prognosis, and therapeutic monitoring. This review synthesizes current evidence regarding the most clinically relevant biomarkers of epithelial injury in chronic ear disease, discusses their pathophysiological significance, and highlights practical implications for clinicians in diagnosis, management, and risk stratification.

Introduction

Chronic ear diseases, encompassing chronic suppurative otitis media (CSOM), chronic non-suppurative otitis media, and cholesteatoma, represent a complex interplay of persistent infection, ongoing inflammation, and epithelial barrier dysfunction. These conditions are characterized by chronic mucosal and epithelial injury leading to structural damage, hearing impairment, and, in severe cases, intracranial complications. Traditionally, diagnosis and disease monitoring have relied on clinical examination and imaging; however, the identification of molecular biomarkers is transforming our approach, potentially allowing for earlier diagnosis, individualized therapy, and improved outcomes. This review aims to provide a comprehensive overview of established and emerging biomarkers indicative of epithelial injury in chronic ear disease, with an emphasis on recent evidence and clinical relevance.

Epidemiology / Disease Burden

Chronic ear diseases affect millions globally, with a disproportionately higher prevalence in low- and middle-income countries due to limited healthcare access and recurrent infections. CSOM alone is estimated to affect 65-330 million people worldwide, with up to 60% experiencing hearing loss. Cholesteatoma, although less common, accounts for significant surgical interventions and complications. The chronicity and recurrence of these diseases underscore an ongoing burden of epithelial injury and highlight the need for advances in disease monitoring and management, including the integration of molecular biomarkers into clinical practice.

Pathophysiology

The pathogenesis of chronic ear disease is defined by persistent inflammation, impaired epithelial repair, and dysregulated immune responses. The middle ear mucosa and epithelial lining are persistently exposed to microbial pathogens and inflammatory mediators, resulting in the release of cytokines (e.g., IL-1β, TNF-α), matrix metalloproteinases (MMP-2, MMP-9), and epithelial cell-derived markers such as cytokeratins and S100 proteins. In cholesteatoma, aberrant keratinocyte proliferation and differentiation, driven by sustained epithelial injury, further contribute to bone erosion and tissue destruction. The identification of specific biomarkers reflecting these processes is critical for elucidating disease activity and progression.

Risk Factors

Key risk factors for chronic ear disease and sustained epithelial injury include recurrent upper respiratory tract infections, eustachian tube dysfunction, genetic predisposition, immunodeficiency, poor socioeconomic conditions, and environmental exposures such as tobacco smoke and overcrowding. These factors contribute to the chronicity of inflammation and impaired mucosal defense, predisposing patients to repeated epithelial trauma and delayed healing. Understanding the interplay of risk factors is essential for targeted preventive and therapeutic strategies, particularly in high-risk populations.

Clinical Features

Chronic ear diseases present with persistent otorrhea, conductive or mixed hearing loss, tympanic membrane perforation, and, in the case of cholesteatoma, progressive bone destruction and potential for intracranial extension. The clinical course is often punctuated by periods of exacerbation and remission, with the degree of epithelial injury correlating with symptom severity and risk of complications. Despite advances in otoscopic assessment and imaging, subclinical disease activity and risk of progression remain challenges, emphasizing the need for adjunctive molecular markers to refine clinical evaluation.

Diagnosis

Diagnosis of chronic ear disease relies on a combination of clinical assessment, otoscopy, audiometry, and imaging modalities such as CT and MRI. However, these tools may lack sensitivity for early epithelial injury or subclinical disease activity. Molecular biomarkers have emerged as valuable adjuncts, with studies highlighting elevated levels of MMP-9, cytokeratin 19 fragments (CYFRA 21-1), S100A8/A9, and pro-inflammatory cytokines in middle ear effusions and tissue samples. These biomarkers reflect active epithelial injury and inflammation, providing opportunities for earlier diagnosis, disease stratification, and monitoring of therapeutic response.

Treatment & Management

Management principles for chronic ear disease focus on eradication of infection, control of inflammation, restoration of epithelial integrity, and prevention of complications. Conventional approaches include topical and systemic antibiotics, corticosteroids, and surgical interventions such as tympanoplasty and mastoidectomy, particularly for cholesteatoma. The integration of biomarker assessment into clinical practice holds promise for individualized therapy, allowing for early identification of patients at risk for persistent epithelial injury, monitoring of treatment efficacy, and prediction of recurrence.

Recent Advances / Emerging Therapies

Recent research has identified novel biomarkers and therapeutic targets associated with epithelial injury, including the role of microRNAs (miR-21, miR-146a), exosomal proteins, and epithelial cell-derived cytokines as mediators of mucosal remodeling and repair. Targeted therapies modulating MMP activity, oxidative stress, and epithelial regeneration are under investigation, with early-phase trials demonstrating potential for reduced tissue damage and improved hearing outcomes. The application of multiplex biomarker panels and point-of-care assays may soon enable rapid risk stratification and personalized management in the clinical setting.

Guideline Recommendations

Current clinical guidelines emphasize the importance of early identification and intervention in chronic ear disease to prevent progression and complications. While biomarker-based diagnostics are not yet standard of care, emerging evidence supports their adjunctive use in complex or refractory cases. Consensus statements advocate for multidisciplinary collaboration, incorporation of molecular profiling in research protocols, and ongoing evaluation of biomarker utility in large, prospective cohorts. As the evidence base grows, it is anticipated that guideline updates will increasingly incorporate biomarker-driven approaches to optimize patient outcomes.

Conclusion

The identification and clinical application of biomarkers of epithelial injury represent a paradigm shift in the diagnosis and management of chronic ear disease. Advances in molecular profiling have enhanced our understanding of disease mechanisms and provided opportunities for earlier detection, individualized therapy, and improved prognostication. Continued research and integration of biomarker assessment into routine clinical practice hold promise for optimizing outcomes, reducing disease burden, and advancing the standard of care for patients with chronic ear pathology.